Compare ADMA Biologics Inc (ADMA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs VICI Properties Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while VICI Properties Inc trades at $26.03 (market cap $28.71B). The key difference: VICI Properties Inc is far larger — about 13.2× ADMA Biologics Inc's market cap, and VICI Properties Inc pays a 6.9% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | VICI | |
|---|---|---|
Market Cap | $2.18B | $28.71B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $33.78 |
52-Week Low | $7.60 | $25.94 |
Enterprise Value | $2.25B | $46.26B |
Dividend Yield | — | 6.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
VICI Properties trades at $26.74, up 0.66% today, with a neutral technical signal and strong fundamentals including a 67.5% net income margin and a P/E of 10.1. Recent Q2 2026 earnings showed an EPS miss but revenue beat, while the company raised its full-year AFFO guidance. A $1.75 billion note offering in August 2026 supports capital deployment.
The outlook remains positive with a 76.9% analyst buy rating and a $29.83 consensus price target, offering potential upside. Risks include earnings volatility and high debt, but the near 7% dividend yield and stable cash flows provide investor appeal in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
